-
NMPA Announcement on Including the Testing Methods for Azelaic Acid and Its Salts in Cosmetics and Other 5 Testing Methods into the Technical Specification for the Safety of Cosmetics (Edition 2015) (No. 45, 2024)
2025-02-19
The National Medical Products Administration (NMPA) has organized to formulate Testing Methods for Azelaic Acid and Its Salts in Cosmetics and other 5 testing methods, which have been reviewed and approved by the Chairman's Meeting of the NMPA's Cosmetic Standardization Technical Committee.
-
Provisions for Medical Device Registration and Filing
2024-06-05
Promulgated by SAMR Decree No. 47, issued on August 26, 2021 and shall go into effect as of October 1, 2021
-
Provisions for In-vitro Diagnostic Reagent Registration and Filing
2024-06-05
Promulgated by SAMR Decree No. 48, issued on August 26, 2021 and shall go into effect as of October 1, 2021
-
Provisions for Toothpaste Regulation
2024-06-05
Promulgated by SAMR Decree No. 71, issued on March 16, 2023 and shall go into effect as of December 1, 2023
-
NMPA Announcement on Provisions for Cosmetic Inspections (No. 52, 2024)
2024-04-29
To strengthen the supervision and administration and regulate cosmetic inspections, according to the Regulations on Supervision and Administration of Cosmetics, the Provisions for Registration and Notification of Cosmetics and the Provisions for Supervision and Administration of Cosmetic Manufacturing and Distribution, the NMPA formulated the Provisions for Cosmetic Inspections, which is hereby issued and will come into force from November 1, 2024.
-
NMPA Announcement on the Matters Related to Optimizing the Application for Marketing and Registration of Drugs Manufactured Overseas and Marketed in China to be Transferred to Domestic Manufacturing
2024-04-23
To further optimize the foreign investment environment, promote the high-quality development in the pharmaceutical industry, improve the drug accessibility, and meet our people’s need, in accordance with the requirements of the Opinions on Further Optimizing the Foreign Investment Environment and Increasing the Efforts to Attract Foreign Investments (GF [2023] No. 11) issued by State Council, and the NMPA Announcement on Provisions for Post-approval Changes of Drugs (Interim) (No. 8, 2021), regarding the optimization of the application procedures for marketing and registration of drugs manufactured overseas and marketed in China to be transferred to domestic manufacturing, the relevant matters are hereby announced as follows.